New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 26, 2014
08:02 EDTABBVAbbVie initiates Phase 3 study of Veliparib for advanced breast cancer
AbbVie initiated a Phase III clinical trial evaluating the safety and efficacy of its investigational compound, veliparib, when added to carboplatin and paclitaxel, two chemotherapeutic medicines, in patients with advanced breast cancer. The randomized, double-blind, Phase III clinical trial will recruit approximately 270 patients. The primary efficacy outcome of the trial is progression-free survival. The secondary pre-specified outcome measures include overall survival, clinical benefit rate, objective response rate and duration of response.
News For ABBV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 27, 2015
07:07 EDTABBVBiogen, AbbVie say EMA validates MAA for Zinbryta for treatment of MS
Biogen (BIIB) and AbbVie (ABBV) announced that the European Medicines Agency has validated the companies’ Marketing Authorisation Application for ZINBRYTA for the treatment of relapsing forms of multiple sclerosis in the European Union. Validation confirms that the submission is complete and signifies the initiation of the review process by the EMA’s Committee for Medicinal Products for Human Use. The MAA included results from two clinical trials, DECIDE and SELECT, in which ZINBRYTA 150 mg was administered subcutaneously every four weeks in people with relapsing-remitting MS. Biogen and AbbVie are jointly developing ZINBRYTA.
March 23, 2015
09:03 EDTABBVLeerink analysts hold a meeting with a conference call hookup
Subscribe for More Information
07:17 EDTABBVAmerican Academy of Dermatology to hold annual meeting
73rd Annual Meeting of AAD is being held in San Francisco on March 20-24.
March 20, 2015
07:41 EDTABBVAmerican Academy of Dermatology to hold annual meeting
Subscribe for More Information
March 19, 2015
08:47 EDTABBVAbbVie and C2N sign worlwide license agreement for Alzheimer's Disease therapy
AbbVie has entered into an exclusive worldwide license agreement with C2N Diagnostics, a privately held protein diagnostic and therapeutic discovery company, to develop and commercialize a portfolio of anti-tau antibodies for the treatment of Alzheimer's Disease and other neurological disorders. Financial terms of the collaboration were not disclosed.
07:56 EDTABBVAbbVie plans $30M expansion at plant in Puerto Rico, AP reports
AbbVie is planning to expand one of its facilities in Barceloneta, Puerto Rico, The Associated Press reports. The $30M expansion is slated for a plant that manufactures products related to immunology, virology and metabolic disorders. Reference Link
March 17, 2015
08:03 EDTABBVAbbVie to present data from 22 HUMIRA abstracts at AAD
Subscribe for More Information
06:31 EDTABBVStudies find Gilead's hepatitis C drugs cost effective, Reuters says
Subscribe for More Information
March 16, 2015
15:04 EDTABBVPharmacyclics says committee recommends unblinding after primary endpoint met
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use